-+ 0.00%
-+ 0.00%
-+ 0.00%

Sobi's Aspaveli maintains proteinuria reduction, stabilizes kidney function at 76 weeks

PUBT·10/19/2026 08:22:03
Sobi's Aspaveli maintains proteinuria reduction, stabilizes kidney function at 76 weeks
  • Sobi will present seven Aspaveli/Empaveli abstracts at ASN Kidney Week, October 21-25, 2026, in Denver.
  • The 76-week results show sustained reductions in urinary protein leakage with stable kidney function in C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis.
  • Two oral presentations include pediatric findings from VALIANT and its VALE extension.
  • Five posters cover renal safety, treatment experience and additional research, including the Phase 4 PRISM-C3 real-world effectiveness and safety study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Swedish Orphan Biovitrum AB published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.